## Diagnosis: Renal Oncocytoma **Key Point:** The combination of **central scar with spoke-wheel enhancement on CT** and **biopsy showing cells with abundant mitochondria and perinuclear halos ('vegetable cell' appearance)** is pathognomonic for **renal oncocytoma** — a benign renal tumor with no malignant potential. **High-Yield:** Renal oncocytoma arises from the **intercalated cells (Type A) of the collecting duct** and accounts for ~3–7% of all renal masses. It is the most common benign solid renal tumor in adults. ## Histopathological Features | Feature | Oncocytoma | Chromophobe RCC | | --- | --- | --- | | **Origin** | Intercalated cells (Type A) of collecting duct | Intercalated cells of collecting duct | | **Cytoplasm** | Deeply eosinophilic; packed with mitochondria | Pale/clear; mitochondria present but fewer | | **Characteristic Cell** | Round cells with granular cytoplasm; perinuclear halos | "Vegetable cells" with prominent perinuclear halos | | **Immunohistochemistry** | CK7 focal+, CD117+, Hale's colloidal iron negative | CK7 diffuse+, CD117+, Hale's colloidal iron positive | | **Genetics** | Loss of chromosome 1 and/or 14; mitochondrial mutations | Monosomy 1, 2, 6, 10, 13, 17, 21 | | **Prognosis** | **Benign — no malignant potential** | Malignant but better prognosis than clear cell RCC | | **Metastatic Rate** | **Zero (benign)** | ~5–10% | ## Why Oncocytoma and Not Chromophobe RCC? **Clinical Pearl:** While both oncocytoma and chromophobe RCC share mitochondria-rich cells and overlapping histology, the **key distinguishing features** in this stem are: 1. **Imaging**: Central scar with spoke-wheel enhancement is the **classic CT hallmark of oncocytoma** (Robson & Bhatt, Radiology). Chromophobe RCC can occasionally show a central scar but is less characteristic. 2. **Histology**: The 'vegetable cell' appearance with **perinuclear halos** is described in both, but in the context of a benign-appearing, well-circumscribed, homogeneous mass on imaging, oncocytoma is the primary diagnosis. 3. **Prognostic advantage**: Oncocytoma is **entirely benign** with no metastatic potential — a far greater prognostic advantage over clear cell RCC than chromophobe RCC (which is still malignant). ## Prognostic Advantage of Oncocytoma vs. Clear Cell RCC 1. **No malignant potential**: Oncocytoma does not metastasize; clear cell RCC metastasizes in ~20–30% of cases. 2. **Benign behavior**: Even large oncocytomas (>4 cm) do not require aggressive oncologic surgery in confirmed cases; active surveillance or nephron-sparing approaches are acceptable. 3. **No cancer-specific mortality**: 5-year cancer-specific survival is effectively 100% for pure oncocytoma vs. ~70–75% for clear cell RCC (Harrison's Principles of Internal Medicine, 21st ed.). ## Differential Diagnosis: Why Not the Others? - **Chromophobe RCC (D)**: Still a malignancy with metastatic potential (~5–10%); does not have the same "no malignant potential" advantage as oncocytoma. The stem's imaging and biopsy findings best fit oncocytoma. - **Papillary RCC (A)**: Shows papillary architecture on biopsy, not vegetable cells with perinuclear halos; intermediate prognosis. - **Clear Cell RCC (C)**: Lipid-rich clear cells on biopsy; VHL mutation; worse prognosis; does not match the described histology. **Key Point (per Robbins & Cotran Pathologic Basis of Disease, 10th ed.):** Oncocytoma is a benign neoplasm of the kidney composed of large eosinophilic cells (oncocytes) with abundant mitochondria. The central stellate scar on imaging is a classic but not pathognomonic feature; definitive diagnosis requires biopsy showing the characteristic oncocytic morphology with perinuclear halos. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.